Coronavirus - COVID - 19 information and updates Click Here
Shiven B. Patel, MD, MBA, FACP
Call to Schedule (208) 356-4673

 

Language(s):

Gender:
English Male

 

Shiven B. Patel MD MBA FACP

Shiven B. Patel, MD, MBA, FACP, is an Assistant Professor in the Division of Oncology, Department of Medicine, at the University of Utah, School of Medicine, and an investigator at the Huntsman Cancer Institute. Dr. Patel is a specialist in adult hematology and medical oncology, and his main areas of interest include thoracic (head & neck, thyroid, lung, mesothelioma, and thymic cancers). Dr. Patel earned his bachelor’s and medical degrees from The University of Florida in Gainesville, Florida. He then went on to complete an Internal Medicine residency at the University of Maryland School Of Medicine in Baltimore, Maryland. Next, he served as an attending physician in Hospitalist Medicine at MedStar Franklin Square in Rosedale, Maryland. Dr. Patel then completed a combined fellowship in hematology and oncology at the University of Utah and the Huntsman Cancer Institute. He served as the Chief Fellow in his final year of training and sat on the Graduate Medical Education Committee at the University of Utah. Most recently, he completed the MBA program at Indiana University, Kelley School of Business in Indianapolis, Indiana, as well as the Lean Six Sigma Green Belt Certification, through Professional Education at the University of Utah in Salt Lake City. Dr. Patel is board certified in internal medicine, hematology, and oncology. He is a member of several national organizations such as the American Society of Clinical Oncology, American Society of Hematology, and American Association of Cancer Research. Throughout his medical training, Dr. Patel has been involved in both laboratory and clinical research. He has presented his work at multiple national meetings and published these findings in peer-review articles. He is a co-investigator in a number of clinical trials at the Huntsman Cancer Institute and is working to bring more studies of all phases to benefit his patients to the Huntsman Cancer Institute.

Shiven B. Patel, MD, MBA, FACP

 

RESEARCH INTERESTS

  • Lung Cancer
  • Hematology
  • Mesothelioma
  • Thymoma
  • Thoracic Oncology

BOARD CERTIFICATION AND ACADEMIC INFORMATION

Academic Departments Internal Medicine – Assistant Professor (Clinical)
Academic Divisions Oncology
Board Certification American Board of Internal Medicine
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)

 

Graduate Training – Indiana University, Kelley School of Business
Business of Medicine
M.B.A.
Fellowship – Huntsman Cancer Institute and Veterans Affairs Hospital
Hematology and Oncology
Chief Fellow
Fellowship – Huntsman Cancer Institute and Veterans Affairs Hospital
Hematology and Oncology
Fellow
Residency – University of Maryland Medical System and Baltimore VA Medical Center
Internal Medicine
Resident
Internship – University of Maryland Medical System and Baltimore VA Medical Center
Internal Medicine
Intern
Professional Medical – University of Florida College of Medicine
Medicine
M.D.
Undergraduate – University of Florida College of Liberal Arts and Sciences
Major: Basic Biology & Medicine; Minor: Business Administration
B.S.
Undergraduate – the University of Florida, College of Liberal Arts and Sciences
Honors Program
A.A.
Certification – University of Utah
Lean Six Sigma Green Belt, Professional Education
Certification

Shiven B. Patel, MD, MBA, FACP is in good standing with Madison Memorial Hospital and has privileges here. Some of his privileges as an oncologist in our specialty clinic include the following:

Some of the privileges Shiven B. Patel, MD, MBA, FACP enjoy are evaluation and Management of the following:

Medical Oncology

Hematology/BMT

Lung Cancer

 

SELECTED PUBLICATIONS – JOURNAL ARTICLES

Journal Article

  1. Baron K, Moser JC, Patel S, Grossmann KF, Colonna SV, Hyngstrom JR (2020). Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies. J Oncol Pharm Pract, 1078155220924719.
  2. Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR (2020). Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol, 1-4.
  3. Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, JOP1900329.
  4. Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA (2020). NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. J Natl Compr Canc Netw, 18(1), 12-22.
  5. Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. (Epub ahead of print) Target Oncol.
  6. Johnson ED, Kerrigan K, Butler K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract, 1078155219835912.
  7. Boothe D, Clyde JW, Christensen M, Patel SB, Lloyd S (2018). A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy. J Radiat Oncol, 7(3), 223-232.
  8. Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal Sumanta K, Stenehjem DD, Agarwal N (2018). Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. J Oncol Pharm Pract, 3, 190-197.
  9. Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L (2017). Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(12), 1520-1541.
  10. Patel S, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Reshmi S, Gastier-Foster JM, Schiffman JD, Miles RR (2017). Genomic analysis of adult B-ALL identifies potential markers of shorter survival. Leuk Res, 56, 44-51.
  11. Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N (2017). Neutrophil-lymphocyte ratio as a predictive biomarker for response to high does interleukin-2 in patients with renal cell carcinoma. BMC Urology.
  12. Agarwal N, Alex AB, Farnham JM, Patel SB, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L (2016). Inherited variants in SULT1E1 and response to abiraterone acetate in men with metastatic castration refractory prostate cancer (mCRPC). J Urol.
  13. Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N (2016). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clin Genitourin Cancer, 14(2), 153-9.
  14. Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N (2015). Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clin Genitourin Cancer, 13(3), e131-7.
  15. Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N (2015). Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. J Oncol, 2015, 181926.
  16. Reese Z, Patel S, Stenehjem DD, Garrido-Laguna I (2014). Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. J Gastrointest Cancer, 45 Suppl 1, 278-81.
  17. Julian D, April KL, Patel S, Stein JR, Wohlgemuth SE (2005). Mitochondrial depolarization following hydrogen sulfide exposure in erythrocytes from a sulfide-tolerant marine invertebrate. J Exp Biol, 208(Pt 21), 4109-22.

Review

  1. Patel SB, Gill D, Garrido-Laguna I (2016). Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. [Review]. Onco Targets Ther, 9, 75-86.

Case Report

  1. Patel SB, Gojo I, Tidwell ML, Sausville EA, Baer MR (2011). Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma, 52(7), 1211-4.

Editorial

  1. Patel SB, Tuan J (2021). A Community Perspective: Latest 340B Program’s Effect on Cancer Centers. https://dailynews.ascopubs.org/do/10.1200/ADN.21.200434/full/.

Letter

  1. Patel SB, Rodgers GM (2014). Continuous infusion of human plasma-derived von Willebrand factor concentrate as an effective therapy in a patient with acquired von Willebrand disease. [Letter to the editor]. Haemophilia, 20(6), e411-4.

Abstract

  1. Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. doi: https://doi.org/10.1016/j.cllc.2021.01.013 [Abstract].
  2. Neal JW, Lim FL, Felip E, Gentzler RD, Patel SB, Baranda J, Fang B, Squillante CM, Simonelli M, Werneke S, Curran D, Aix SP (2020). Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. (suppl) abstr 9610 [Abstract]. 38.
  3. Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.doi:10.1002/cam4.2625 [Abstract].
  4. Kerrigan K, Haaland B, Adamson B, Patel S, Akerley W (2019). P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers [Abstract]. 14(10), S369-S370.
  5. Lim F, Ponce S, Patel S, Van Herpen C, Kurkjian C, Lou Y, Liu Y, Ramsingh G, Pal S, Neal J (2019). P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) [Abstract]. 14(10), S405-S406.
  6. Kerrigan, K, Haaland B, Adamson B, Patel S, Akerley W (2019). MA14.09 Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer [Abstract]. 14(10), S307-S308.
  7. Moser J, Wei G, Colonna S, Grossmann KF, Patel S, Hyngstrom J (2019). Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma [Abstract]. 30.
  8. Johnson ED, Kerrigan K, Bulter K, Patel SB (2019). Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy [Abstract]. Journal of Oncology Pharmacy Practice.
  9. Coman G, Moser J, Hyngstrom J, Grossmann K, Patel SB, Colonna S, Andtbacka R (2018). Overall Survival of Patients Treated with Single Agent Ipilimumab or Combination Nivolumab and Ipilimumab in Second Line Setting After Progression on Frontline Anti-PD-1 Therapy [Abstract].
  10. Chalmers A, Haaland B, Patel SB, Moynahan K, Cannon L, Akerley W (2018). P3.01-13 Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC) [Abstract]. Journal of Thoracic Oncology, 13(10), S872.
  11. Patel SB, Akerley WL, Ose D, Haydell T, Martineau J, Dunson WA, Chalmers AW, Cannon L, Meropol NJ, Haaland B (2018). Prognostic value of patient-reported outcomes (PROs) in advanced cancer [Abstract]. Journal of Clinical Oncology, 36.
  12. McPherson JP, Patel SB, Igumnova E, Pettit J, Ose D, Haydell T, Martineau J, Meropol NJ, Beck AC (2018). Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL) [Abstract]. Journal of Clinical Oncology, 36.
  13. Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson WA, Chalmers AW, Cannon L, Kissell B, Meropol NJ, Akerley WL (2018). Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer (abstr 10101) [Abstract]. Journal of Clinical Oncology, 36(15).
  14. Boothe D, Clyde JW, Christensen M, Patel SB, Lloyd S (2018). A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy [Abstract]. (7), 223–232.
  15. Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn AW, Gupta S, Alex A, Patel S, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 35(6S suppl), abstract 265.
  16. Thibault J, Patel SB (2017). A Case of Mytomycin-C Induced Pulmonary Veno-Occlusive Disease [Abstract]. AVAHO Updates.
  17. Agarwal N, Heemers H, Farnham JM, Patel SB, Gill DM, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr 5066.
  18. Alex A, Stenehjem DD, Twardowski P, Cheng HH, Gill DM, Buckley H, Patel SB, Kessler ER, Chittoria N, Poudel A, Vaishampayan UN, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone-sensitive metastatic prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr 5083.
  19. Kuzman JA, Stenehjem DD, Patel SB, Merriman J, Gill DM, Hahn A, Agarwal AM, Gupta S, Albertson D, Alex A, Agarwal N (2016). Neutrophil-lymphocyte ratio (NLR) as a predictive biomarker for response to high dose interleukin 2 (HDIL-2) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(suppl), abstr e 16087.
  20. Buckley TH, Alex A, Franham JM, Gill DM, Patel SB, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphisms (SNPs) in SULT1E1 with response to treatment with abiraterone acetate (AA) in men with metastatic castration refractory prostate cancer (mCRPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 222.
  21. Alex A, Stenehjem DD, Twardowski P, Cheng HH, Buckley TH, Gill DM, Patel SB, Vaishampayan U, Agarwal N (2016). Impact of prior definitive therapy on survival outcomes in men with new hormone sensitive metastatic prostate cancer (mHSPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 269.
  22. Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 610.
  23. Au TH, Bailey EB, Patel SB, Tantravahi SK, Agarwal N, Stenehjem DD (2016). Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 608.
  24. Gill DM, Alex A, Farnham JM, Buckley TH, Patel SB, Agarwal AM, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA, Agarwal N (2016). Association of single nucleotide polymorphism in four genes and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC) [Abstract]. Journal of Clinical Oncology, 34(2S suppl), abstr 224.
  25. Agarwal N, Buckley TH, Farnham JM, Patel SB, Agarwal A, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Alex A, Cannon-Albright LA (2016). Association of single nucleotide polymorphisms (SNPs) in STS and SULT2B1 and response to androgen deprivation therapy (ADT) in men with advanced hormone sensitive prostate cancer (aHSPC) [Abstract]. Clinical Cancer Research, 22(1 suppl), 39.
  26. Patel SB, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Reshmi SR, Gastier-Foster JM, Schiffman JD, Miles RR (2015). Genomic analysis of adult B-ALL identifies changes in copy number profile at relapse and IKZF1/CDKN2A co-deletion at diagnosis as a marker of shorter survival [Abstract]. Blood, 126(23), 1427.
  27. Patel SB, Buckley TH, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone (T) and serum prostate-specific antigen (PSA) at 7 months (7 mo PSA) in patients with new hormone sensitive metastatic prostate cancer (mHSPC) treated with continuous androgen deprivation therapy (cADT) [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 231.
  28. Patel SB, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Schiffman JD, Miles RR (2015). IKZF1/CDKN2A Co-Deletion Predicts Shorter Survival in Adult B-ALL [Abstract]. Cancer Research, 75(15 suppl), 1723.
  29. Patel SB, Buckley TH, Gill D, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone and serum prostate-specific antigen at 7 months in patients with new hormone sensitive metastatic prostate cancer treated with continuous androgen deprivation therapy [Abstract]. Journal of Clinical Oncology, 33(15 suppl), e16019.
  30. Patel SB, Stenehjem DD, Hsu J, Tantravahi SK, Gill D, Agarwal A, Batten JA, Agarwal N, Pal SK (2015). Comparative effectiveness of first line vascular endothelial growth factor inhibitor followed by second line therapy with either a VEGF-TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(15 suppl), e15589.
  31. Buckley TH, Patel SB, Tantravahi SK, Batten JA, Stenehjem DD, Alex A, Agarwal N (2015). Correlation of baseline serum testosterone and serum prostate-specific antigen at 7 months in patients with new hormone sensitive metastatic prostate cancer treated with continuous androgen deprivation therapy [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 231.
  32. Reese ZL, Tometich D, Patel SB, Sharma S, Garrido-Laguna I (2015). Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012 [Abstract]. Journal of Clinical Oncology, 33(3 suppl), abstr 311.
  33. Patel SB, Tometich D, Reese ZL, Sharma S, Garrido-Laguna I (2015). Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002-2012 [Abstract]. Journal of Clinical Oncology, 33(3 suppl), 687-687.
  34. Agarwal N, Buckley TH, Farnham JM, Patel SB, Alex A, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Germline predictors of response to androgen deprivation therapy in men with advanced prostate cancer [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 162.
  35. Patel SB, Agarwal N, Hsu J, Tantravahi SK, Gill D, Vuong W, Batten JA, Stenehjem DD, Pal SK (2015). Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 460.
  36. Patel SB, Tantravahi SK, Gill D, Poole A, Merriman J, Batten JA, Stenehjem DD, Agarwal N (2015). Comparative effectiveness of first line vascular endothelial growth factor inhibitor followed by second line therapy with either a VEGF-TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 495.
  37. Tantravahi SK, Patel SB, Ravulapati S, Batten J, Merriman J, Stenehjem DD, Agarwal N (2015). Long term response in metastatic renal cell carcinoma patients receiving first line therapy with vascular endothelial growth factor inhibitors with VEGF TKIs [Abstract]. Journal of Clinical Oncology, 33(7 suppl), abstr 436.
  38. Agarwal N, Alex A, Farnham JM, Patel SB, Tantravahi SK, Teerlink C, Albright FS, Stephenson RA, Cannon-Albright LA (2015). Association of single nucleotide polymorphisms in ESR1 and PRMT8 and response to treatment with abiraterone acetate in men with metastatic castration refractory prostate cancer [Abstract]. Journal of Clinical Oncology, 33(suppl), abstr 5048.
  39. Patel SB, Gojo I, Tidwell M, Sausville EA, Baer MR (2011). Subdural hematomas in patients with Philadelphia chromosome positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy [Abstract]. Journal of Clinical Oncology, 29(15 suppl), abstr 6579.
  40. Patel SB, Gojo I, Tidwell M, Ning Y, Zhao XF, Sausville EA, Baer MR (2011). Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multi-agent chemotherapy [Abstract]. Journal of Clinical Onocology, 29(suppl), abstr 6579.

 

 

 

 

Please reach out to Idaho Huntsman Cancer Institute to see what insurances are accepted by them.

Madison Cancer Care Center – Huntsman Cancer Institute Affiliate

MadisonMemorial.org
450 E Main St, Rexburg, ID 83440
(208) 356-4673

 

Specialty

Medical Oncology
Lung Cancer
Hematology/BMT